Brief: Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
24/06/2025 12:04
June 24 (Reuters) - iBio Inc IBIO.O: IBIO AND ASTRALBIO UNVEIL OBESITY PROGRAM WITH NOVEL AMYLIN AGONIST ANTIBODY DEMONSTRATING PROMISING IN VIVO RESULTS IBIO INC - ANTIBODY-BASED AGONISTS SHOW POTENTIAL FOR OBESITY AND CARDIOMETABOLIC DISEASES IBIO INC - AMYLIN RECEPTOR AGONIST ANTIBODY REDUCES FOOD INTAKE IN MOUSE MODEL Source text: ID:nGNXb0L8SQ Further company coverage: IBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on iBio
See all newsBrief: iBio - IBIO-610 Plus Semaglutide Preserves Lean Mass In Eight-Week Obese NHP Study
Brief: Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update
Brief: Ibio Reports Q3 Fiscal Year 2026 Financial Results And Provides Corporate Update
U.S. STOCKS ON THE MOVE-Meta, Legence, Chegg
U.S. STOCKS ON THE MOVE-Hims & Hers, Chewy, Longeveron